Here are the S-3 shelf registrations from Traws Pharma, Inc. (TRAW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-3 covers the shelf registration that lets an established company sell over time, so if you follow TRAW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TRAW filings page.
Traws Pharma, Inc. files a registration statement on Form S-3 to register up to $139,185,641.25 of unsold securities pursuant to Rule 415(a)(6). The filing replaces the company’s prior registration statement and covers offers of common stock, preferred stock, debt securities, warrants and units, to be sold from time to time.
The prospectus states the aggregate offering price limit of $139,185,641.25, describes permitted distribution methods, and notes incorporated reports (including the 2025 Form 10-K). The audit report for 2025 includes a going-concern explanatory paragraph.
Traws Pharma, Inc. files a registration on Form S-3 to permit resale by selling stockholders of up to 35,897,514 shares of its common stock. The shares comprise Initial Shares and shares issuable upon exercise of Pre-Funded Warrants and Series A, B and C Warrants.
The prospectus states the company will not receive proceeds from resales by selling stockholders; the company would receive cash only if the Warrants are exercised for cash. The filing notes 15,150,669 shares outstanding as of April 24, 2026 for table calculations and lists listing on NASDAQ under TRAW.